EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma

Oncology Reports

Volumn 23, Issue 2, 2010, Pages 563-570

  Chen, Gang ^a   Wang, Yi ^a   Zhou, Mengtao ^a   Shi, Hongqi ^a   Yu, Zhengping ^a   Zhu, Yefan ^a   Yu, Fuxiang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; EphA1; Hepatocellular carcinoma; siRNA

Indexed keywords

EPHRIN RECEPTOR A1; GELATINASE A; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; METASTASIS; MICROVASCULATURE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NIH 3T3 CELLS; RECEPTOR, EPHA1; RNA, SMALL INTERFERING; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 76649136182     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000670     Document Type: Article

References (48)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. Poon RT, Ng IO, Lau C, et al: Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20: 1775-1785, 2002.
3. Tanigawa N, Lu C, Mitsui T and Miura S: Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 26: 1216-1223, 1997.
4. Sugimachi K, Tanaka S, Terashi T, Taguchi K, Rikimaru T and Sugimachi K: The mechanisms of angiogenesis in hepatocellular carcinoma:angiogenic switch during tumor progression. Surgery 131 (Suppl): S135-S141, 2002.
5. Yancopoulos G, Davis S, Gale NW, Rudge JS, Weigand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
6. Flanagan JG and Vanderhaeghen P: The ephrins and Eph receptors in neural development. Annu Rev Neurosci 21: 309-345, 1998.
7. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR and Kinch MS: EphA2 over-expression causes tumorigenesis of mammary epithelial cells. Cancer Res 61: 2301-2306, 2001.
8. Walker-Daniels J, Coffman K, Azimi M, et al: Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 41: 275-280, 1999.
9. Kinch MS, Moore MB and Harpole DH: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9: 613-618, 2003.
10. Shao Z, Zhang WF, Chen XM and Shang ZJ: Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol 44: 1110-1117, 2008.
11. Oshima T, Akaike M, Yoshihara K, et al: Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer. Int J Oncol l33: 573-577, 2008.
12. Nakamura R, Kataoka H, Sato N, et al: EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci 96: 42-47, 2005.
13. Nemoto T, Ohashi K, Akashi T, Johnson JD and Hirokawa K: Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 65: 195-203, 1997.
14. Easty DJ, Hill SP, Hsu MY, et al: Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 84: 494-501, 1999.
15. Wu D, Suo Z, Kristensen GB, et al: Prognostic value of EphA2 and Ephrin-A1 in squamous cell cervical carcinoma. Gynecol Oncol 94: 312-319, 2004.
16. Alam SM, Fujimoto J, Jahan I, Sato E and Tamaya T: Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br J Cancer 98: 845-851, 2008.
17. Nasreen N, Mohammed KA, Lai Y and Antony VB: Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Cancer Lett 258: 215-222, 2007.
18. Dobrzanski P, Hunter K, Jones-Bolin S, et al: Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64: 910-919, 2004.
19. Brantley DM, Cheng N, Thompson EJ, et al: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21: 7011-7026, 2002.
20. Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D and Chen J: Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res 66: 10315-10324, 2006.
21. Hirai H, Maru Y, Hagiwara K, Nishida J and Takaku F: A novel putative tyrosine kinase receptor encoded by the eph gene. Science 238: 1717-1720, 1987.
22. Robinson D, He F, Pretlow T and Kung HJ: A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 93: 5958-5962, 1996.
23. Kao HW, Chen HC, Wu CW and Lin WC: Tyrosine-kinase expression profiles in human gastric cancer cell lines and their modulations with retinoic acids. Br J Cancer 88: 1058-1064, 2003.
24. Maru Y, Hirai H, Yoshida MC and Takaku F: Evolution, expression and chromosomal location of a novel receptor tyrosine kinase gene, eph. Mol Cell Biol 8: 3770-3776, 1998.
25. Iida H, Honda M, Kawai HF, et al: Ephrin-A1 expression contributes to the malignant characteristics of α-fetoprotein producing hepatocellular carcinoma. GUT 53: 843-851, 2005.
26. Maru Y, Hirai H and Takaku F: Overexpression confers an oncogenic potential upon the eph gene. Oncogene 5: 445-447, 1990.
27. Brantley-Sieders D, Schmidt S, Parker M and Chen J: Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 27: 3431-3442, 2004.
28. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
29. Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553, 2002.
30. Holen T, Amarzguioui M, Wiiger MT, Babaie E and Prydz H: Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res 30: 1757-1766, 2002.
31. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001.
32. Elbashir SM, Lendeckel W and Tuschl T: RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev 15: 188-200, 2001.
33. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515, 2000.
34. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
35. Yoshiji H, Kuriyama S, Yoshii J, et al: Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28: 1489-1496, 1998.
36. Tait CR and Jones PF: Angiopoietins in tumors: the angiogenic switch. J Pathol 204: 1-10, 2004.
37. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K and Wands JR: Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103: 341-345, 1999.
38. Yoshiji H, Kuriyama S, Yoshii J, et al: Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35: 834-842, 2002.
39. Yoshiji H, Kuriyama S, Noguchi R, et al: Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 54: 1768-1775, 2005.
40. Cheng N, Brantley DM, Liu H, et al: Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1: 2-11, 2002.
41. Chen J, Hicks D, Brantley-Sieders D, et al: Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp Eye Res 82: 664-673, 2006.
42. Kuyvenhoven JP, van Hoek B, Blom E, et al: Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma. Thromb Haemost 89: 718-725, 2003.
43. Giannelli G, Bergamini C, Marinosci F, et al: Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 97: 425-431, 2002.
44. Määttä M, Soini Y, Liakka A and Autio-Harmainen H: Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 6: 2726-2734, 2000.
45. Arii S, Mise M, Harada T, et al: Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24: 316-322, 1996.
46. Mayoral R, Fernández-Martínez A, Boscá L and Martín-Sanz P: Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 26: 753-761, 2005.
47. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S and Mori M: Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 61: 2145-2153, 2001.
48. Bergers G, Brekken R, McMahon G, et al: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744, 2000.